Chad Dubbelde Appointed as 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝗖𝗗𝗢 𝗦𝗮𝗹𝗲𝘀 at Samsung Biologics – 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀

Chad Dubbelde appointed as 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝗖𝗗𝗢 𝗦𝗮𝗹𝗲𝘀 at Samsung Biologics – 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀

Samsung Biologics proudly announces the appointment of Chad Dubbelde as Director, CDO Sales, effective June 2025. With a distinguished career that bridges cutting-edge science, strategic business development, and client-focused growth, Chad brings over two decades of experience to one of the world’s leading biopharmaceutical contract development and manufacturing organizations (CDMOs).

This milestone appointment reflects Samsung Biologics’ commitment to accelerating biopharma innovation, driving transformative partnerships, and delivering next-generation biologics to patients worldwide.

𝗣𝘂𝘀𝗵𝗶𝗻𝗴 𝘁𝗵𝗲 𝗕𝗼𝘂𝗻𝗱𝗮𝗿𝗶𝗲𝘀 𝗼𝗳 𝗖𝗗𝗠𝗢 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲

Samsung Biologics leverages its unrivaled expertise in biologics development to deliver tailored CDMO solutions that support clients from gene to IND and beyond. In his role as Director of CDO Sales, Chad is tasked with fostering trust-driven collaborations, accelerating clinical milestones, and advancing large molecule therapeutics into the clinic with speed, precision, and reliability.

Speaking about his vision, Chad noted:

“Every partnership we build has the potential to transform patient outcomes. At Samsung Biologics, I see an incredible opportunity to not only support clients in their journey from discovery to development, but also to redefine what’s possible in biologics innovation.”

𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗥𝗼𝗼𝘁𝗲𝗱 𝗶𝗻 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲

Chad’s professional journey demonstrates a consistent ability to connect scientific insight with strategic business execution. At Charles River Laboratories, where he spent over six years, Chad played a pivotal role in shaping the biologics testing solutions business.

• As Business Development Director (2024–2025), he drove client acquisition in the Boston market, building solutions that emphasized collaboration and client-centricity.
• As Regional Sales Manager for Western North America (2022–2023), he expanded market reach in San Diego, establishing regional leadership in biologics testing.
• Earlier as Business Development Director (2019–2021), he laid the foundation for long-term growth by combining technical acumen with strategic account management.

Through these roles, Chad solidified his reputation for a results-driven, customer-focused approach that seamlessly integrates scientific expertise with business strategy.

𝗔 𝗗𝗶𝘃𝗲𝗿𝘀𝗲 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 𝗼𝗳 𝗜𝗺𝗽𝗮𝗰𝘁

Beyond Charles River, Chad’s career reflects a wide-ranging impact across industries:

• At BioSurplus (2016–2019), he supported life sciences innovation by providing laboratory solutions tailored to research needs.
• At Cargill (2008–2013), he drove 10% CAGR revenue growth in the specialty chemical sector through transformative marketing and product strategies.
• As an Independent Consultant (2007–2008), he advised C-level executives with deep market research, financial valuation models, and strategic feasibility studies.

Earlier in his career, Chad laid a strong scientific foundation with research positions at Adaptive Therapeutics, Elitra Pharmaceuticals, Howard Hughes Medical Institute (HHMI), and Washington University School of Medicine’s Genome Institute, contributing to infectious disease therapeutics and the Human Genome Project.

𝗖𝗵𝗮𝗿𝘁𝗶𝗻𝗴 𝗮 𝗡𝗲𝘄 𝗖𝗼𝘂𝗿𝘀𝗲 𝗳𝗼𝗿 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮

In joining Samsung Biologics, Chad steps into a role that is not just about sales, but about shaping the future of biopharmaceutical partnerships. His mission is to connect science with strategy, innovation with execution, and ambition with outcomes.

“Science alone doesn’t change the world—science delivered with purpose does,” Chad reflects. “At Samsung Biologics, I am committed to helping clients navigate complexity, accelerate innovation, and bring life-saving therapies to patients faster than ever before.”

𝗧𝗵𝗲 𝗥𝗼𝗮𝗱 𝗔𝗵𝗲𝗮𝗱

Chad’s appointment signals a new chapter of growth and innovation for Samsung Biologics. With his unique blend of research expertise, commercial leadership, and visionary thinking, he is poised to play a transformative role in advancing the company’s mission and shaping the future of the global biopharma ecosystem.

Samsung Biologics continues to stand at the forefront of biologics innovation — and with leaders like Chad driving its mission forward, the company is well-positioned to redefine what partnership, progress, and patient impact truly mean in the biopharmaceutical industry.

This announcement is proudly featured on CXO Gateway, a platform that highlights visionary leadership and celebrates executives driving transformation across industries. By sharing journeys like Chad Dubbelde’s, CXO Gateway continues to connect global leaders with ideas that inspire change.